{"id":212,"date":"2019-07-24T00:00:00","date_gmt":"2019-07-24T00:00:00","guid":{"rendered":"https:\/\/norrismclaughlin.com\/lg\/2019\/07\/24\/fda-warns-cannabis-operator-curaleaf-about-cbd-marketing-claims\/"},"modified":"2019-07-24T00:00:00","modified_gmt":"2019-07-24T00:00:00","slug":"fda-warns-cannabis-operator-curaleaf-about-cbd-marketing-claims","status":"publish","type":"post","link":"https:\/\/norrismclaughlin.com\/lg\/in-the-news\/fda-warns-cannabis-operator-curaleaf-about-cbd-marketing-claims\/","title":{"rendered":"FDA Warns Cannabis Operator Curaleaf About CBD Marketing Claims"},"content":{"rendered":"

Yesterday, the FDA issued another Warning Letter<\/a> in connection with the sale of CBD products, this time to well-known cannabis purveyor Curaleaf, Inc. (which operates one of our six medical dispensaries here in New Jersey and operates four dispensaries in New York).\u00a0 In a contemporaneous news release<\/a> that announced the Warning Letter, the FDA took the opportunity to reinforce its ongoing position that its primary focus is to protect the health and safety of American consumers while also balancing the interests and demands of the market.<\/p>\n

The FDA admonished Curaleaf for claiming that its CBD products, which it offers in various forms such as lotions, patches, and tinctures, could relieve chronic pain, offer relief from anxiety and ADHD, is shown to be effective in treating Parkinson\u2019s disease, has been linked to effective treatment of Alzheimer\u2019s disease, and even has been demonstrated to have properties that counteract the growth of spread of cancer.\u00a0 The Warning Letter advised that certain Curaleaf products were unapproved new drugs sold in violation of the Food, Drug, and Cosmetic Act (\u201cFD&C Act\u201d), and that a number of products were misbranded.\u00a0 The Warning Letter further explained that these \u201cdrugs\u201d did not have adequate directions for use.\u00a0 The FDA also informed Curaleaf that it was improper to market its CBD products as dietary supplements because CBD is an active ingredient in a drug product that has been approved under section 505 of the FD&C Act, the exception for substances that were \u201cmarketed as\u201d a dietary supplement or as a conventional food before the new drug investigations were authorized did not apply, and because some products, such as the lotions, patches, and vape pens, are not intended for ingestion.\u00a0 The Warning Letter also took issue with Curaleaf\u2019s CBD products directed to pets, because the FDA deems those products to be unapproved new animal drugs.<\/p>\n

Curaleaf now has 15 days to respond to the FDA and explain how it will correct the violations.\u00a0 The company has publicly stated that it intends to respond by that deadline, and emphasized it will cooperate with the FDA, and that it is committed to compliance:<\/p>\n

Curaleaf is committed to the highest standards of quality and compliance, and will work collaboratively with the FDA to resolve all issues addressed in the agency’s letter. The Company will respond to the FDA letter within the required 15 working days. Compliance is a top priority for Curaleaf and the Company is fully committed to complying with FDA requirements for all of the products that it markets.\u00a0We can affirm that nothing in the letter raises any issues concerning the quality and consistency of any Curaleaf product or calls into question the high safety standards of the Company’s cultivation and manufacturing processes.\u00a0Curaleaf CBD products are all derived from hemp and meet the requirements of the Farm Bill.\u201d<\/p><\/blockquote>\n

This Warning Letter comes just five days after Curaleaf announced its acquisition of GR Companies, Inc.<\/a>, the largest private vertically-integrated multi-state operator, in a cash and stock deal valued at about $875 million.\u00a0 Curaleaf says that the acquisition will make it the world\u2019s largest cannabis company by revenue and one of the largest operators in the United States.\u00a0 Curaleaf\u2019s stock closed up 18% the day it announced the acquisition. \u00a0Following the release of the Warning Letter, Curaleaf saw its stock price take a hit, closing down 3.23%.<\/p>\n

If it were not already clear enough, the issuance of this Warning Letter to one of the country\u2019s leading cannabis companies should eliminate any confusion about claiming unsubstantiated health benefits in the marketing of CBD products \u2013 do so at your own risk, and don\u2019t be surprised if you end up in the FDA\u2019s crosshairs.<\/p>\n

\n
\n
If you have any questions about this post or any other related matters, please feel free to contact our Cannabis Law Practice Group<\/a>.<\/section>\n<\/section>\n<\/section>\n","protected":false},"excerpt":{"rendered":"

Yesterday, the FDA issued another Warning Letter in connection with the sale of CBD products, this time to well-known cannabis purveyor Curaleaf, Inc. (which operates one of our six medical dispensaries here in New Jersey and operates four dispensaries in New York).\u00a0 In a contemporaneous news release that announced the Warning Letter, the FDA took […]<\/p>\n","protected":false},"author":151,"featured_media":209,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[42,30],"tags":[5,191,192],"coauthors":[],"acf":[],"yoast_head":"\nFDA Warns Cannabis Operator Curaleaf About CBD Marketing Claims - Legally Grown<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/norrismclaughlin.com\/lg\/in-the-news\/fda-warns-cannabis-operator-curaleaf-about-cbd-marketing-claims\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"FDA Warns Cannabis Operator Curaleaf About CBD Marketing Claims\" \/>\n<meta property=\"og:description\" content=\"Yesterday, the FDA issued another Warning Letter in connection with the sale of CBD products, this time to well-known cannabis purveyor Curaleaf, Inc. (which operates one of our six medical dispensaries here in New Jersey and operates four dispensaries in New York).\u00a0 In a contemporaneous news release that announced the Warning Letter, the FDA took […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/norrismclaughlin.com\/lg\/in-the-news\/fda-warns-cannabis-operator-curaleaf-about-cbd-marketing-claims\/\" \/>\n<meta property=\"og:site_name\" content=\"Legally Grown\" \/>\n<meta property=\"article:published_time\" content=\"2019-07-24T00:00:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/norrismclaughlin.com\/lg\/wp-content\/uploads\/sites\/18\/2022\/12\/FDA-Approve-Stamp.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2121\" \/>\n\t<meta property=\"og:image:height\" content=\"1414\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Norris McLaughlin Cannabis Law Group\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Norris McLaughlin Cannabis Law Group\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/norrismclaughlin.com\/lg\/in-the-news\/fda-warns-cannabis-operator-curaleaf-about-cbd-marketing-claims\/\",\"url\":\"https:\/\/norrismclaughlin.com\/lg\/in-the-news\/fda-warns-cannabis-operator-curaleaf-about-cbd-marketing-claims\/\",\"name\":\"FDA Warns Cannabis Operator Curaleaf About CBD Marketing Claims - Legally Grown\",\"isPartOf\":{\"@id\":\"https:\/\/norrismclaughlin.com\/lg\/#website\"},\"datePublished\":\"2019-07-24T00:00:00+00:00\",\"dateModified\":\"2019-07-24T00:00:00+00:00\",\"author\":{\"@id\":\"https:\/\/norrismclaughlin.com\/lg\/#\/schema\/person\/c40f8e2088d0b3892a80cf60d6e5a22c\"},\"breadcrumb\":{\"@id\":\"https:\/\/norrismclaughlin.com\/lg\/in-the-news\/fda-warns-cannabis-operator-curaleaf-about-cbd-marketing-claims\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/norrismclaughlin.com\/lg\/in-the-news\/fda-warns-cannabis-operator-curaleaf-about-cbd-marketing-claims\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/norrismclaughlin.com\/lg\/in-the-news\/fda-warns-cannabis-operator-curaleaf-about-cbd-marketing-claims\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/norrismclaughlin.com\/lg\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"FDA Warns Cannabis Operator Curaleaf About CBD Marketing Claims\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/norrismclaughlin.com\/lg\/#website\",\"url\":\"https:\/\/norrismclaughlin.com\/lg\/\",\"name\":\"Legally Grown\",\"description\":\"Cannabis Law Blog\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/norrismclaughlin.com\/lg\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/norrismclaughlin.com\/lg\/#\/schema\/person\/c40f8e2088d0b3892a80cf60d6e5a22c\",\"name\":\"Norris McLaughlin Cannabis Law Group\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/norrismclaughlin.com\/lg\/#\/schema\/person\/image\/76fbbd3507e7d17be42940b88a2f89ca\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/bd8853eb26707dce66f1773640893a72?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/bd8853eb26707dce66f1773640893a72?s=96&d=mm&r=g\",\"caption\":\"Norris McLaughlin Cannabis Law Group\"},\"sameAs\":[\"http:\/\/wordpress-599075-1937274.cloudwaysapps.com\/practice-areas\/cannabis-law\/\"],\"url\":\"https:\/\/norrismclaughlin.com\/lg\/author\/cannabislawteam\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"FDA Warns Cannabis Operator Curaleaf About CBD Marketing Claims - Legally Grown","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/norrismclaughlin.com\/lg\/in-the-news\/fda-warns-cannabis-operator-curaleaf-about-cbd-marketing-claims\/","og_locale":"en_US","og_type":"article","og_title":"FDA Warns Cannabis Operator Curaleaf About CBD Marketing Claims","og_description":"Yesterday, the FDA issued another Warning Letter in connection with the sale of CBD products, this time to well-known cannabis purveyor Curaleaf, Inc. (which operates one of our six medical dispensaries here in New Jersey and operates four dispensaries in New York).\u00a0 In a contemporaneous news release that announced the Warning Letter, the FDA took […]","og_url":"https:\/\/norrismclaughlin.com\/lg\/in-the-news\/fda-warns-cannabis-operator-curaleaf-about-cbd-marketing-claims\/","og_site_name":"Legally Grown","article_published_time":"2019-07-24T00:00:00+00:00","og_image":[{"width":2121,"height":1414,"url":"https:\/\/norrismclaughlin.com\/lg\/wp-content\/uploads\/sites\/18\/2022\/12\/FDA-Approve-Stamp.jpg","type":"image\/jpeg"}],"author":"Norris McLaughlin Cannabis Law Group","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Norris McLaughlin Cannabis Law Group","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/norrismclaughlin.com\/lg\/in-the-news\/fda-warns-cannabis-operator-curaleaf-about-cbd-marketing-claims\/","url":"https:\/\/norrismclaughlin.com\/lg\/in-the-news\/fda-warns-cannabis-operator-curaleaf-about-cbd-marketing-claims\/","name":"FDA Warns Cannabis Operator Curaleaf About CBD Marketing Claims - Legally Grown","isPartOf":{"@id":"https:\/\/norrismclaughlin.com\/lg\/#website"},"datePublished":"2019-07-24T00:00:00+00:00","dateModified":"2019-07-24T00:00:00+00:00","author":{"@id":"https:\/\/norrismclaughlin.com\/lg\/#\/schema\/person\/c40f8e2088d0b3892a80cf60d6e5a22c"},"breadcrumb":{"@id":"https:\/\/norrismclaughlin.com\/lg\/in-the-news\/fda-warns-cannabis-operator-curaleaf-about-cbd-marketing-claims\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/norrismclaughlin.com\/lg\/in-the-news\/fda-warns-cannabis-operator-curaleaf-about-cbd-marketing-claims\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/norrismclaughlin.com\/lg\/in-the-news\/fda-warns-cannabis-operator-curaleaf-about-cbd-marketing-claims\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/norrismclaughlin.com\/lg\/"},{"@type":"ListItem","position":2,"name":"FDA Warns Cannabis Operator Curaleaf About CBD Marketing Claims"}]},{"@type":"WebSite","@id":"https:\/\/norrismclaughlin.com\/lg\/#website","url":"https:\/\/norrismclaughlin.com\/lg\/","name":"Legally Grown","description":"Cannabis Law Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/norrismclaughlin.com\/lg\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/norrismclaughlin.com\/lg\/#\/schema\/person\/c40f8e2088d0b3892a80cf60d6e5a22c","name":"Norris McLaughlin Cannabis Law Group","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/norrismclaughlin.com\/lg\/#\/schema\/person\/image\/76fbbd3507e7d17be42940b88a2f89ca","url":"https:\/\/secure.gravatar.com\/avatar\/bd8853eb26707dce66f1773640893a72?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/bd8853eb26707dce66f1773640893a72?s=96&d=mm&r=g","caption":"Norris McLaughlin Cannabis Law Group"},"sameAs":["http:\/\/wordpress-599075-1937274.cloudwaysapps.com\/practice-areas\/cannabis-law\/"],"url":"https:\/\/norrismclaughlin.com\/lg\/author\/cannabislawteam\/"}]}},"_links":{"self":[{"href":"https:\/\/norrismclaughlin.com\/lg\/wp-json\/wp\/v2\/posts\/212"}],"collection":[{"href":"https:\/\/norrismclaughlin.com\/lg\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/norrismclaughlin.com\/lg\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/norrismclaughlin.com\/lg\/wp-json\/wp\/v2\/users\/151"}],"replies":[{"embeddable":true,"href":"https:\/\/norrismclaughlin.com\/lg\/wp-json\/wp\/v2\/comments?post=212"}],"version-history":[{"count":0,"href":"https:\/\/norrismclaughlin.com\/lg\/wp-json\/wp\/v2\/posts\/212\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/norrismclaughlin.com\/lg\/wp-json\/wp\/v2\/media\/209"}],"wp:attachment":[{"href":"https:\/\/norrismclaughlin.com\/lg\/wp-json\/wp\/v2\/media?parent=212"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/norrismclaughlin.com\/lg\/wp-json\/wp\/v2\/categories?post=212"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/norrismclaughlin.com\/lg\/wp-json\/wp\/v2\/tags?post=212"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/norrismclaughlin.com\/lg\/wp-json\/wp\/v2\/coauthors?post=212"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}